专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008080110A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR 审中-公开
标题翻译：使用神经保护剂和受体酪氨酸激酶抑制剂治疗恶性肿瘤和病理性血管生成的方法
公开(公告)号：WO2008080110A1
公开(公告)日：2008-07-03
申请号：PCT/US2007/088669
申请日：2007-12-21
申请人： ALCON, INC. , BINGAMAN, David P. , COLLIER, JR., Robert J. , LANDERS, Robert A. , RHOADES, Kristina L.
发明人： BINGAMAN, David P. , COLLIER, JR., Robert J. , LANDERS, Robert A. , RHOADES, Kristina L.
IPC分类号： A61K31/416 , A61K31/42 , A61P27/02
CPC分类号： A61K31/42 , A61K31/416
摘要： The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis and providing neuroprotection of the affected retina via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more neuroprotectants.
摘要翻译：本发明提供了通过施用有效抑制选择性受体酪氨酸激酶（RTK）或血管内皮生长因子（VEGF）的一种或多种分子的组合来抑制增加的血管通透性和/或病理性眼血管生成并提供受影响的视网膜的神经保护的方法）和一种或多种神经保护剂。

2. 发明申请

WO2005063249A1 AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION 审中-公开
标题翻译：用于治疗糖尿病肾病和乳腺癌形成的代谢物
公开(公告)号：WO2005063249A1
公开(公告)日：2005-07-14
申请号：PCT/US2004/042562
申请日：2004-12-17
申请人： ALCON, INC. , LANDERS, Robert A. , BINGAMAN, David P.
发明人： LANDERS, Robert A. , BINGAMAN, David P.
IPC分类号： A61K31/497
CPC分类号： A61K31/26 , A61K31/352 , A61K31/497
摘要： Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.
摘要翻译：在年龄相关性黄斑变性中治疗糖尿病性视网膜病变或玻璃疣形成的方法中提供了刺激Nrf2蛋白的核易位和随后增加解毒和消除细胞毒性代谢物的基因产物的试剂。作用于Nrf2 / ARE途径的结构不同的试剂诱导具有化学通用的细胞保护性质的酶和蛋白质的表达，并且是防止有毒代谢物和异生物。药剂包括某些亲电试剂和氧化剂如迈克尔加成受体，二酚，硫代氨基甲酸酯，醌，1,2-二硫杂环戊烯-3-硫酮，丁基化羟基苯甲醚，除了染料木黄酮以外的类黄酮，异硫氰酸酯，3,5-二叔丁基 - 4-羟基甲苯，乙氧喹，香豆素，其组合，或其药理活性衍生物或类似物。

3. 发明公开

EP1696926A1 AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION 审中-公开
标题翻译：用于治疗糖尿病性视网膜病和德鲁兹地层IN黄斑变性
公开(公告)号：EP1696926A1
公开(公告)日：2006-09-06
申请号：EP04814710.2
申请日：2004-12-17
申请人： Alcon, Inc.
发明人： LANDERS, Robert A. , BINGAMAN, David P.
IPC分类号： A61K31/497 , A61P27/02 , A61K31/352 , A61K31/26
CPC分类号： A61K31/26 , A61K31/352 , A61K31/497
摘要： Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式